Remove Antibody Remove Bacteria Remove Bacterium Remove Protein
article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Overall, 66.3

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). Moreover, the response did not induce symptoms typical of a food allergy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

SARS-CoV-2 is characterized by an outer surface speckled with spike proteins, giving it a crown-like appearance, hence the name “corona,” which is the Latin word for crown. The spike protein is critical for binding to ACE2 receptors on host cells — this interaction mediates the entry of the virus into cells. Drug Approvals.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Johnson & Johnson’s Top 5 Best-Selling Drugs of 2022: 1) Stelara (ustekinumab) Stelara is an immunosuppressant biologic therapy that blocks the IL-12 and IL-23 proteins that play a role in plaque psoriasis and Crohn’s disease. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).

Sales 98
article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1